Acute Myeloid Leukemia

Lorus Therapeutics announces presentation on GTI-2040 uptake by tumor cells in AML

Published in Genetics and Environmental Business Week, November 30th, 2006

Lorus Therapeutics, Inc., (LRP), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, announced presentation of GTI-2040 pharmacokinetics in patients with acute myeloid leukemia at the American Association of Pharmaceutical Scientists meeting in San Antonio, Texas.

The presentation entitled "Population Pharmacokinetics (PK) of GTI-2040 in Patients with Acute Myeloid Leukemia (AML)" reports uptake of GTI-2040 in distinct subcellular compartments of leukemic cells at levels that exceeded plasma levels. The uptake of GTI-2040 was measured through an ultrasensitive analytic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week

Source: Genetics and Environmental Business Week (2006-11-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry